Michinobu Tanaka

发表

Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan

H. Hagiyama, N. Miyasaka, T. Takeuchi, 2017, Modern rheumatology.

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Taichi Hayashi, T. Sumida, N. Miyasaka, 2015, Arthritis Research & Therapy.

Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis

S. Ito, T. Sumida, N. Miyasaka, 2012, Arthritis care & research.

Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

S. Ito, N. Miyasaka, T. Sawada, 2011, The Journal of Rheumatology.

Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients.

N. Miyasaka, H. Nakashima, H. Sugiyama, 2011, Pulmonary pharmacology & therapeutics.

Increased IL-15 production of muscle cells in polymyositis and dermatomyositis.

N. Kamatani, Michinobu Tanaka, M. Harigai, 2002, International immunology.

Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia

Y. Takasaki, N. Miyasaka, Kazuyoshi Saito, 2015, Modern rheumatology.

Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment.

N. Kamatani, Michinobu Tanaka, M. Harigai, 2002, The Journal of rheumatology.

Amplification of the synovial inflammatory response through activation of mitogen-activated protein kinases and nuclear factor kappaB using ligation of CD40 on CD14+ synovial cells from patients with rheumatoid arthritis.

Miki Nakagawa, N. Kamatani, Michinobu Tanaka, 2004, Arthritis and rheumatism.

Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study

Y. Takasaki, H. Hagiyama, N. Miyasaka, 2015, The Journal of Rheumatology.

Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients

S. Sawada, A. Ogata, N. Miyasaka, 2012, Modern rheumatology.

Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan

N. Miyasaka, T. Koike, H. Yamazaki, 2016, Modern rheumatology.

Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.

N. Kamatani, Michinobu Tanaka, M. Harigai, 2002, The Journal of rheumatology.

Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents

R. Sakai, Michinobu Tanaka, R. Koike, 2015, The Journal of Rheumatology.

The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis

S. Ito, N. Miyasaka, Yoshiya Tanaka, 2011 .

Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan.

H. Shimizu, Y. Umezawa, M. Takata, 2004, American journal of human genetics.

Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg–Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG

N. Miyasaka, Michinobu Tanaka, T. Nanki, 2012, Modern rheumatology.

PRIMARY SQUAMOUS CELL CARCINOMA OF THE THYROID GLAND -REPORT OF TWO CASES-

Michinobu Tanaka, D. Tanabe, K. Uemura, 1988 .

Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-γ and anti-double-stranded DNA antibody production

N. Kamatani, Michinobu Tanaka, M. Harigai, 2006, Arthritis research & therapy.

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules

S. Ito, T. Sumida, N. Miyasaka, 2012, Annals of the rheumatic diseases.

Pneumocystisjirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors

N. Miyasaka, Yoshiya Tanaka, Y. Ota, 2012, Modern rheumatology.

Membranoproliferative glomerulonephritis and leukocytoclastic vasculitis without cryoglobulin in chronic hepatitis C virus infection.

Michinobu Tanaka, H. Imaeda, A. Suwa, 2003, Internal medicine.

Prominent splenic microcalcifications in a patient with systemic lupus erythematosus complicated by antiphospholipid syndrome.

N. Miyasaka, Y. Nonomura, Michinobu Tanaka, 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Pneumocystisjirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors

N. Miyasaka, Yoshiya Tanaka, Y. Ota, 2012, Modern rheumatology.

Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin.

N. Kamatani, K. Nishimura, Michinobu Tanaka, 2007, The Journal of rheumatology.

Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.

A. Taniguchi, N. Kamatani, H. Nakajima, 2000, Arthritis and rheumatism.

Association between adult-onset Still's disease and interleukin-18 gene polymorphisms

N. Kamatani, Michinobu Tanaka, M. Harigai, 2002, Genes and Immunity.

Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors

N. Miyasaka, K. Saito, Y. Ota, 2012, Modern rheumatology.

Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis.

N. Kamatani, Michinobu Tanaka, M. Harigai, 2001, The Journal of rheumatology.

Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents

R. Sakai, Michinobu Tanaka, R. Koike, 2015, Journal of Rheumatology.

Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells.

N. Kamatani, Michinobu Tanaka, M. Harigai, 2001, The Journal of rheumatology.